Pfm Health Sciences, LP Apellis Pharmaceuticals, Inc. Transaction History

Pfm Health Sciences, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$55.39 - $72.47 $4.59 Million - $6.01 Million	82,952 New	82,952 $4.88 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $749,240 - $911,732	-9,771 Reduced 3.44%	274,498 $25 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $1.59 Million - $2.29 Million	-34,153 Reduced 10.73%	284,269 $18.8 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $8.5 Million - $12 Million	196,542 Added 161.26%	318,422 $16.5 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $5.46 Million - $8.49 Million	121,880 New	121,880 $8.32 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.